The non-small cell lung cancer market consists of therapies used for treatment of the most common type of lung cancer. Non-small cell lung cancer therapies have improved survival rates and quality of life for patients.
The global non-small cell lung cancer market size is estimated to be valued at US$ 31394.67 Bn in 2024 and is expected to exhibit a CAGR of 7.8% over the forecast period between 2024 to 2031.
Key Takeaways
Key players operating in the non-small cell lung cancer market are AstraZeneca Plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo, Inc., Eli Lilly and Company, Merck & Co., Inc., Otsuka Pharmaceutical Company, Ltd., Sanofi, and The Medicines Company.
The increasing incidence of lung cancer and development of Non-Small Cell Lung Cancer Market Demand Globally, there were over 2 million new cases of lung cancer in 2020. Furthermore, non-small cell lung cancer accounts for around 85% of all lung cancer cases. This growing prevalence of the disease is driving demand for improved treatment options. Additionally, a robust pipeline with several targeted drugs in clinical trials will support market expansion during the forecast period.
Key players operating in the non-small cell lung cancer are increasingly investing in R&D to develop novel targeted therapies. For instance, AstraZeneca received FDA approval for Tagrisso as a first-line treatment in 2020. Some other notable drugs launched recently include IMFINZI by AstraZeneca and Genentech's Tecentriq. This growing availability of targeted options with better efficacy rates compared to chemotherapy is positively impacting the market.
The Non-Small Cell Lung Cancer Companies is witnessing strong growth worldwide. As per the World Lung Cancer Coalition, over 2.2 million new cases of lung cancer are reported globally each year. Consequently, companies are actively expanding their geographic footprint, especially in emerging countries in Asia Pacific and Latin America. Furthermore, these regions are expected to outpace global average growth rates due to rising healthcare expenditures over the coming years.
Market Key Trends
The increasing focus on combination therapy regimens remains a key trend in the non-small cell lung cancer market. Clinical trials evaluating targeted drugs in combination as opposed to monotherapy are gaining prominence. Combinations help maximize therapeutic benefits through complementary mechanisms of action. Some of the ongoing studies evaluating doublet or triplet combinations include IMFINZI + chemotherapy and Tecentriq + Avastin + chemotherapy. This focus on building upon the success of immunotherapy and targeted therapy is expected to translate into improved clinical outcomes over the long term.
Porter’s Analysis
Threat of new entrants:The non-small cell lung cancer market is moderately difficult to enter due to requirements for strong distribution network, skilled workforce and high investments for research and development.
Bargaining power of buyers:The bargaining power of buyers is moderate in this market as healthcare providers have reasonably high bargaining power but need for effective treatment options limits it.
Bargaining power of suppliers:The bargaining power of suppliers is moderate owing to availability of alternative treatment options and raw material suppliers.
Threat of new substitutes:Threat of substitutes is moderate as lung cancer is a complex disease with limited effective non-invasive treatment alternatives available.
Competitive rivalry:The competition is high among key established players to gain higher market share through development of novel combination therapies and targeted drugs.
Geographical regions
North America dominates the non-small cell lung cancer market currently in terms of value share owing to high acceptance of advanced therapies, availability of reimbursements and presence of major players.
Asia Pacific is poised to be the fastest growing regional market during the forecast period due to increasing healthcare expenditures, rising incidence of lung cancer and growing awareness. Countries like China and India will be key focus areas.
Get More Insights On, Non-Small Cell Lung Cancer Market
For More Insights Discover the Report In language that Resonates with you
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)